Global Biosimilar Monoclonal Antibodies Market Insights and Forecast to 2028

The global Biosimilar Monoclonal Antibodies market size is estimated to be worth US$ 5320.8 million in 2022 and is forecast to a readjusted size of US$ 12960 million by 2028 with a CAGR of 16.0% during the review period. Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

Fully considering the economic change by this health crisis, Infliximab accounting for % of the Biosimilar Monoclonal Antibodies global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Oncology segment is altered to an % CAGR throughout this forecast period.

Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%. Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.

In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.

The authors of this research report have explored the key segments: Type and Application. The report offers an in-depth breakdown of type and application segments and their sub-segments. The lucrativeness and growth potential have been looked into by the industry experts in this report. This section of the report also provides sales and revenue forecast data by type and application segments based on sales, price, and revenue for the period 2017-2028. The specialists, to broaden the understanding of the users, have done value chain and raw material analysis in this section.

• Infliximab
• Rituximab
• Trastuzumab
• Adalimumab
• Other

• Oncology
• Autoimmune Disease
• Other

The authors of this study have enlightened the readers on the rise and effect of the Covid-19 outbreak on the development. They have investigated the changes brought about in the demand/supply side, consumption, supply chain, and sales/manufacturing. The readers will get familiar with the measures that have helped the key players to bring the Biosimilar Monoclonal Antibodies market back to the pre-covid levels.

In this segment of the report, the specialists have delved into the key growth opportunities that are likely to emerge. This will aid the key players to simplify complex issues related to business and frame future strategies to compete in this competitive environment. This section will certainly assist the players to boldly position their business.

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Asia-Pacific
• China
• Japan
• South Korea
• India
• Australia
• Taiwan
• Indonesia
• Thailand
• Malaysia
• Philippines
• Vietnam
• Latin America
• Mexico
• Brazil
• Argentina
• Middle East & Africa
• Turkey
• Saudi Arabia
• U.A.E

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and share analysis of the prominent players are also provided in this section. They have also provided reliable sales and revenue data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

• Celltrion
• Pfizer (Hospira)
• 3SBIO
• Novartis (Sandoz)
• Dr Reddy’s
• Celgen Biopharma
• Cadila Healthcare
• Hisun Pharma
• Torrent Pharmaceuticals

1 Study Coverage

    1.1 Biosimilar Monoclonal Antibodies Product Introduction

    1.2 Market by Type

        1.2.1 Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type, 2017 VS 2021 VS 2028

        1.2.2 Infliximab

        1.2.3 Rituximab

        1.2.4 Trastuzumab

        1.2.5 Adalimumab

        1.2.6 Other

    1.3 Market by Application

        1.3.1 Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Application, 2017 VS 2021 VS 2028

        1.3.2 Oncology

        1.3.3 Autoimmune Disease

        1.3.4 Other

    1.4 Study Objectives

    1.5 Years Considered

2 Executive Summary

    2.1 Global Biosimilar Monoclonal Antibodies Sales Estimates and Forecasts 2017-2028

    2.2 Global Biosimilar Monoclonal Antibodies Revenue Estimates and Forecasts 2017-2028

    2.3 Global Biosimilar Monoclonal Antibodies Revenue by Region: 2017 VS 2021 VS 2028

    2.4 Global Biosimilar Monoclonal Antibodies Sales by Region

        2.4.1 Global Biosimilar Monoclonal Antibodies Sales by Region (2017-2022)

        2.4.2 Global Sales Biosimilar Monoclonal Antibodies by Region (2023-2028)

    2.5 Global Biosimilar Monoclonal Antibodies Revenue by Region

        2.5.1 Global Biosimilar Monoclonal Antibodies Revenue by Region (2017-2022)

        2.5.2 Global Biosimilar Monoclonal Antibodies Revenue by Region (2023-2028)

    2.6 North America

    2.7 Europe

    2.8 Asia-Pacific

    2.9 Latin America

    2.10 Middle East & Africa

3 Competition by Manufacturers

    3.1 Global Biosimilar Monoclonal Antibodies Sales by Manufacturers

        3.1.1 Global Top Biosimilar Monoclonal Antibodies Manufacturers by Sales (2017-2022)

        3.1.2 Global Biosimilar Monoclonal Antibodies Sales Market Share by Manufacturers (2017-2022)

        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Biosimilar Monoclonal Antibodies in 2021

    3.2 Global Biosimilar Monoclonal Antibodies Revenue by Manufacturers

        3.2.1 Global Biosimilar Monoclonal Antibodies Revenue by Manufacturers (2017-2022)

        3.2.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Manufacturers (2017-2022)

        3.2.3 Global Top 10 and Top 5 Companies by Biosimilar Monoclonal Antibodies Revenue in 2021

    3.3 Global Biosimilar Monoclonal Antibodies Sales Price by Manufacturers (2017-2022)

    3.4 Analysis of Competitive Landscape

        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

        3.4.2 Global Biosimilar Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

        3.4.3 Global Biosimilar Monoclonal Antibodies Manufacturers Geographical Distribution

    3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

    4.1 Global Biosimilar Monoclonal Antibodies Sales by Type

        4.1.1 Global Biosimilar Monoclonal Antibodies Historical Sales by Type (2017-2022)

        4.1.2 Global Biosimilar Monoclonal Antibodies Forecasted Sales by Type (2023-2028)

        4.1.3 Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2017-2028)

    4.2 Global Biosimilar Monoclonal Antibodies Revenue by Type

        4.2.1 Global Biosimilar Monoclonal Antibodies Historical Revenue by Type (2017-2022)

        4.2.2 Global Biosimilar Monoclonal Antibodies Forecasted Revenue by Type (2023-2028)

        4.2.3 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2017-2028)

    4.3 Global Biosimilar Monoclonal Antibodies Price by Type

        4.3.1 Global Biosimilar Monoclonal Antibodies Price by Type (2017-2022)

        4.3.2 Global Biosimilar Monoclonal Antibodies Price Forecast by Type (2023-2028)

5 Market Size by Application

    5.1 Global Biosimilar Monoclonal Antibodies Sales by Application

        5.1.1 Global Biosimilar Monoclonal Antibodies Historical Sales by Application (2017-2022)

        5.1.2 Global Biosimilar Monoclonal Antibodies Forecasted Sales by Application (2023-2028)

        5.1.3 Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2017-2028)

    5.2 Global Biosimilar Monoclonal Antibodies Revenue by Application

        5.2.1 Global Biosimilar Monoclonal Antibodies Historical Revenue by Application (2017-2022)

        5.2.2 Global Biosimilar Monoclonal Antibodies Forecasted Revenue by Application (2023-2028)

        5.2.3 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2017-2028)

    5.3 Global Biosimilar Monoclonal Antibodies Price by Application

        5.3.1 Global Biosimilar Monoclonal Antibodies Price by Application (2017-2022)

        5.3.2 Global Biosimilar Monoclonal Antibodies Price Forecast by Application (2023-2028)

6 North America

    6.1 North America Biosimilar Monoclonal Antibodies Market Size by Type

        6.1.1 North America Biosimilar Monoclonal Antibodies Sales by Type (2017-2028)

        6.1.2 North America Biosimilar Monoclonal Antibodies Revenue by Type (2017-2028)

    6.2 North America Biosimilar Monoclonal Antibodies Market Size by Application

        6.2.1 North America Biosimilar Monoclonal Antibodies Sales by Application (2017-2028)

        6.2.2 North America Biosimilar Monoclonal Antibodies Revenue by Application (2017-2028)

    6.3 North America Biosimilar Monoclonal Antibodies Market Size by Country

        6.3.1 North America Biosimilar Monoclonal Antibodies Sales by Country (2017-2028)

        6.3.2 North America Biosimilar Monoclonal Antibodies Revenue by Country (2017-2028)

        6.3.3 U.S.

        6.3.4 Canada

7 Europe

    7.1 Europe Biosimilar Monoclonal Antibodies Market Size by Type

        7.1.1 Europe Biosimilar Monoclonal Antibodies Sales by Type (2017-2028)

        7.1.2 Europe Biosimilar Monoclonal Antibodies Revenue by Type (2017-2028)

    7.2 Europe Biosimilar Monoclonal Antibodies Market Size by Application

        7.2.1 Europe Biosimilar Monoclonal Antibodies Sales by Application (2017-2028)

        7.2.2 Europe Biosimilar Monoclonal Antibodies Revenue by Application (2017-2028)

    7.3 Europe Biosimilar Monoclonal Antibodies Market Size by Country

        7.3.1 Europe Biosimilar Monoclonal Antibodies Sales by Country (2017-2028)

        7.3.2 Europe Biosimilar Monoclonal Antibodies Revenue by Country (2017-2028)

        7.3.3 Germany

        7.3.4 France

        7.3.5 U.K.

        7.3.6 Italy

        7.3.7 Russia

8 Asia Pacific

    8.1 Asia Pacific Biosimilar Monoclonal Antibodies Market Size by Type

        8.1.1 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Type (2017-2028)

        8.1.2 Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Type (2017-2028)

    8.2 Asia Pacific Biosimilar Monoclonal Antibodies Market Size by Application

        8.2.1 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Application (2017-2028)

        8.2.2 Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Application (2017-2028)

    8.3 Asia Pacific Biosimilar Monoclonal Antibodies Market Size by Region

        8.3.1 Asia Pacific Biosimilar Monoclonal Antibodies Sales by Region (2017-2028)

        8.3.2 Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region (2017-2028)

        8.3.3 China

        8.3.4 Japan

        8.3.5 South Korea

        8.3.6 India

        8.3.7 Australia

        8.3.8 Taiwan

        8.3.9 Indonesia

        8.3.10 Thailand

        8.3.11 Malaysia

        8.3.12 Philippines

9 Latin America

    9.1 Latin America Biosimilar Monoclonal Antibodies Market Size by Type

        9.1.1 Latin America Biosimilar Monoclonal Antibodies Sales by Type (2017-2028)

        9.1.2 Latin America Biosimilar Monoclonal Antibodies Revenue by Type (2017-2028)

    9.2 Latin America Biosimilar Monoclonal Antibodies Market Size by Application

        9.2.1 Latin America Biosimilar Monoclonal Antibodies Sales by Application (2017-2028)

        9.2.2 Latin America Biosimilar Monoclonal Antibodies Revenue by Application (2017-2028)

    9.3 Latin America Biosimilar Monoclonal Antibodies Market Size by Country

        9.3.1 Latin America Biosimilar Monoclonal Antibodies Sales by Country (2017-2028)

        9.3.2 Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2017-2028)

        9.3.3 Mexico

        9.3.4 Brazil

        9.3.5 Argentina

10 Middle East and Africa

    10.1 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Type

        10.1.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Type (2017-2028)

        10.1.2 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Type (2017-2028)

    10.2 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Application

        10.2.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Application (2017-2028)

        10.2.2 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Application (2017-2028)

    10.3 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Country

        10.3.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2017-2028)

        10.3.2 Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2017-2028)

        10.3.3 Turkey

        10.3.4 Saudi Arabia

11 Company Profiles

    11.1 Celltrion

        11.1.1 Celltrion Corporation Information

        11.1.2 Celltrion Overview

        11.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)

        11.1.4 Celltrion Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

        11.1.5 Celltrion Recent Developments

    11.2 Pfizer (Hospira)

        11.2.1 Pfizer (Hospira) Corporation Information

        11.2.2 Pfizer (Hospira) Overview

        11.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)

        11.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

        11.2.5 Pfizer (Hospira) Recent Developments

    11.3 3SBIO

        11.3.1 3SBIO Corporation Information

        11.3.2 3SBIO Overview

        11.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)

        11.3.4 3SBIO Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

        11.3.5 3SBIO Recent Developments

    11.4 Novartis (Sandoz)

        11.4.1 Novartis (Sandoz) Corporation Information

        11.4.2 Novartis (Sandoz) Overview

        11.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)

        11.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

        11.4.5 Novartis (Sandoz) Recent Developments

    11.5 Dr Reddy’s

        11.5.1 Dr Reddy’s Corporation Information

        11.5.2 Dr Reddy’s Overview

        11.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)

        11.5.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

        11.5.5 Dr Reddy’s Recent Developments

    11.6 Celgen Biopharma

        11.6.1 Celgen Biopharma Corporation Information

        11.6.2 Celgen Biopharma Overview

        11.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)

        11.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

        11.6.5 Celgen Biopharma Recent Developments

    11.7 Cadila Healthcare

        11.7.1 Cadila Healthcare Corporation Information

        11.7.2 Cadila Healthcare Overview

        11.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)

        11.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

        11.7.5 Cadila Healthcare Recent Developments

    11.8 Hisun Pharma

        11.8.1 Hisun Pharma Corporation Information

        11.8.2 Hisun Pharma Overview

        11.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)

        11.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

        11.8.5 Hisun Pharma Recent Developments

    11.9 Torrent Pharmaceuticals

        11.9.1 Torrent Pharmaceuticals Corporation Information

        11.9.2 Torrent Pharmaceuticals Overview

        11.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2017-2022)

        11.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

        11.9.5 Torrent Pharmaceuticals Recent Developments

12 Industry Chain and Sales Channels Analysis

    12.1 Biosimilar Monoclonal Antibodies Industry Chain Analysis

    12.2 Biosimilar Monoclonal Antibodies Key Raw Materials

        12.2.1 Key Raw Materials

        12.2.2 Raw Materials Key Suppliers

    12.3 Biosimilar Monoclonal Antibodies Production Mode & Process

    12.4 Biosimilar Monoclonal Antibodies Sales and Marketing

        12.4.1 Biosimilar Monoclonal Antibodies Sales Channels

        12.4.2 Biosimilar Monoclonal Antibodies Distributors

    12.5 Biosimilar Monoclonal Antibodies Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

    13.1 Biosimilar Monoclonal Antibodies Industry Trends

    13.2 Biosimilar Monoclonal Antibodies Market Drivers

    13.3 Biosimilar Monoclonal Antibodies Market Challenges

    13.4 Biosimilar Monoclonal Antibodies Market Restraints

14 Key Findings in The Global Biosimilar Monoclonal Antibodies Study

15 Appendix

    15.1 Research Methodology

        15.1.1 Methodology/Research Approach

        15.1.2 Data Source

    15.2 Author Details

    15.3 Disclaimer

Table 1. Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)

Table 2. Major Manufacturers of Infliximab

Table 3. Major Manufacturers of Rituximab

Table 4. Major Manufacturers of Trastuzumab

Table 5. Major Manufacturers of Adalimumab

Table 6. Major Manufacturers of Other

Table 7. Global Biosimilar Monoclonal Antibodies Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)

Table 8. Global Biosimilar Monoclonal Antibodies Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)

Table 9. Global Biosimilar Monoclonal Antibodies Sales by Region (2017-2022) & (K Units)

Table 10. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2017-2022)

Table 11. Global Biosimilar Monoclonal Antibodies Sales by Region (2023-2028) & (K Units)

Table 12. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2023-2028)

Table 13. Global Biosimilar Monoclonal Antibodies Revenue by Region (2017-2022) & (US$ Million)

Table 14. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2017-2022)

Table 15. Global Biosimilar Monoclonal Antibodies Revenue by Region (2023-2028) & (US$ Million)

Table 16. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2023-2028)

Table 17. Global Biosimilar Monoclonal Antibodies Sales by Manufacturers (2017-2022) & (K Units)

Table 18. Global Biosimilar Monoclonal Antibodies Sales Share by Manufacturers (2017-2022)

Table 19. Global Biosimilar Monoclonal Antibodies Revenue by Manufacturers (2017-2022) & (US$ Million)

Table 20. Global Biosimilar Monoclonal Antibodies Revenue Share by Manufacturers (2017-2022)

Table 21. Biosimilar Monoclonal Antibodies Price by Manufacturers (2017-2022) &(USD/Unit)

Table 22. Global Biosimilar Monoclonal Antibodies Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 23. Global Biosimilar Monoclonal Antibodies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Monoclonal Antibodies as of 2021)

Table 24. Biosimilar Monoclonal Antibodies Manufacturing Base Distribution and Headquarters

Table 25. Manufacturers Biosimilar Monoclonal Antibodies Product Offered

Table 26. Date of Manufacturers Enter into Biosimilar Monoclonal Antibodies Market

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Biosimilar Monoclonal Antibodies Sales by Type (2017-2022) & (K Units)

Table 29. Global Biosimilar Monoclonal Antibodies Sales by Type (2023-2028) & (K Units)

Table 30. Global Biosimilar Monoclonal Antibodies Sales Share by Type (2017-2022)

Table 31. Global Biosimilar Monoclonal Antibodies Sales Share by Type (2023-2028)

Table 32. Global Biosimilar Monoclonal Antibodies Revenue by Type (2017-2022) & (US$ Million)

Table 33. Global Biosimilar Monoclonal Antibodies Revenue by Type (2023-2028) & (US$ Million)

Table 34. Global Biosimilar Monoclonal Antibodies Revenue Share by Type (2017-2022)

Table 35. Global Biosimilar Monoclonal Antibodies Revenue Share by Type (2023-2028)

Table 36. Biosimilar Monoclonal Antibodies Price by Type (2017-2022) & (USD/Unit)

Table 37. Global Biosimilar Monoclonal Antibodies Price Forecast by Type (2023-2028) & (USD/Unit)

Table 38. Global Biosimilar Monoclonal Antibodies Sales by Application (2017-2022) & (K Units)

Table 39. Global Biosimilar Monoclonal Antibodies Sales by Application (2023-2028) & (K Units)

Table 40. Global Biosimilar Monoclonal Antibodies Sales Share by Application (2017-2022)

Table 41. Global Biosimilar Monoclonal Antibodies Sales Share by Application (2023-2028)

Table 42. Global Biosimilar Monoclonal Antibodies Revenue by Application (2017-2022) & (US$ Million)

Table 43. Global Biosimilar Monoclonal Antibodies Revenue by Application (2023-2028) & (US$ Million)

Table 44. Global Biosimilar Monoclonal Antibodies Revenue Share by Application (2017-2022)

Table 45. Global Biosimilar Monoclonal Antibodies Revenue Share by Application (2023-2028)

Table 46. Biosimilar Monoclonal Antibodies Price by Application (2017-2022) & (USD/Unit)

Table 47. Global Biosimilar Monoclonal Antibodies Price Forecast by Application (2023-2028) & (USD/Unit)

Table 48. North America Biosimilar Monoclonal Antibodies Sales by Type (2017-2022) & (K Units)

Table 49. North America Biosimilar Monoclonal Antibodies Sales by Type (2023-2028) & (K Units)

Table 50. North America Biosimilar Monoclonal Antibodies Revenue by Type (2017-2022) & (US$ Million)

Table 51. North America Biosimilar Monoclonal Antibodies Revenue by Type (2023-2028) & (US$ Million)

Table 52. North America Biosimilar Monoclonal Antibodies Sales by Application (2017-2022) & (K Units)

Table 53. North America Biosimilar Monoclonal Antibodies Sales by Application (2023-2028) & (K Units)

Table 54. North America Biosimilar Monoclonal Antibodies Revenue by Application (2017-2022) & (US$ Million)

Table 55. North America Biosimilar Monoclonal Antibodies Revenue by Application (2023-2028) & (US$ Million)

Table 56. North America Biosimilar Monoclonal Antibodies Sales by Country (2017-2022) & (K Units)

Table 57. North America Biosimilar Monoclonal Antibodies Sales by Country (2023-2028) & (K Units)

Table 58. North America Biosimilar Monoclonal Antibodies Revenue by Country (2017-2022) & (US$ Million)

Table 59. North America Biosimilar Monoclonal Antibodies Revenue by Country (2023-2028) & (US$ Million)

Table 60. Europe Biosimilar Monoclonal Antibodies Sales by Type (2017-2022) & (K Units)

Table 61. Europe Biosimilar Monoclonal Antibodies Sales by Type (2023-2028) & (K Units)

Table 62. Europe Biosimilar Monoclonal Antibodies Revenue by Type (2017-2022) & (US$ Million)

Table 63. Europe Biosimilar Monoclonal Antibodies Revenue by Type (2023-2028) & (US$ Million)

Table 64. Europe Biosimilar Monoclonal Antibodies Sales by Application (2017-2022) & (K Units)

Table 65. Europe Biosimilar Monoclonal Antibodies Sales by Application (2023-2028) & (K Units)

Table 66. Europe Biosimilar Monoclonal Antibodies Revenue by Application (2017-2022) & (US$ Million)

Table 67. Europe Biosimilar Monoclonal Antibodies Revenue by Application (2023-2028) & (US$ Million)

Table 68. Europe Biosimilar Monoclonal Antibodies Sales by Country (2017-2022) & (K Units)

Table 69. Europe Biosimilar Monoclonal Antibodies Sales by Country (2023-2028) & (K Units)

Table 70. Europe Biosimilar Monoclonal Antibodies Revenue by Country (2017-2022) & (US$ Million)

Table 71. Europe Biosimilar Monoclonal Antibodies Revenue by Country (2023-2028) & (US$ Million)

Table 72. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Type (2017-2022) & (K Units)

Table 73. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Type (2023-2028) & (K Units)

Table 74. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Type (2017-2022) & (US$ Million)

Table 75. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Type (2023-2028) & (US$ Million)

Table 76. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Application (2017-2022) & (K Units)

Table 77. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Application (2023-2028) & (K Units)

Table 78. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Application (2017-2022) & (US$ Million)

Table 79. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Application (2023-2028) & (US$ Million)

Table 80. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Region (2017-2022) & (K Units)

Table 81. Asia Pacific Biosimilar Monoclonal Antibodies Sales by Region (2023-2028) & (K Units)

Table 82. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region (2017-2022) & (US$ Million)

Table 83. Asia Pacific Biosimilar Monoclonal Antibodies Revenue by Region (2023-2028) & (US$ Million)

Table 84. Latin America Biosimilar Monoclonal Antibodies Sales by Type (2017-2022) & (K Units)

Table 85. Latin America Biosimilar Monoclonal Antibodies Sales by Type (2023-2028) & (K Units)

Table 86. Latin America Biosimilar Monoclonal Antibodies Revenue by Type (2017-2022) & (US$ Million)

Table 87. Latin America Biosimilar Monoclonal Antibodies Revenue by Type (2023-2028) & (US$ Million)

Table 88. Latin America Biosimilar Monoclonal Antibodies Sales by Application (2017-2022) & (K Units)

Table 89. Latin America Biosimilar Monoclonal Antibodies Sales by Application (2023-2028) & (K Units)

Table 90. Latin America Biosimilar Monoclonal Antibodies Revenue by Application (2017-2022) & (US$ Million)

Table 91. Latin America Biosimilar Monoclonal Antibodies Revenue by Application (2023-2028) & (US$ Million)

Table 92. Latin America Biosimilar Monoclonal Antibodies Sales by Country (2017-2022) & (K Units)

Table 93. Latin America Biosimilar Monoclonal Antibodies Sales by Country (2023-2028) & (K Units)

Table 94. Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2017-2022) & (US$ Million)

Table 95. Latin America Biosimilar Monoclonal Antibodies Revenue by Country (2023-2028) & (US$ Million)

Table 96. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Type (2017-2022) & (K Units)

Table 97. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Type (2023-2028) & (K Units)

Table 98. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Type (2017-2022) & (US$ Million)

Table 99. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Type (2023-2028) & (US$ Million)

Table 100. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Application (2017-2022) & (K Units)

Table 101. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Application (2023-2028) & (K Units)

Table 102. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Application (2017-2022) & (US$ Million)

Table 103. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Application (2023-2028) & (US$ Million)

Table 104. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2017-2022) & (K Units)

Table 105. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2023-2028) & (K Units)

Table 106. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2017-2022) & (US$ Million)

Table 107. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue by Country (2023-2028) & (US$ Million)

Table 108. Celltrion Corporation Information

Table 109. Celltrion Description and Major Businesses

Table 110. Celltrion Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 111. Celltrion Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

Table 112. Celltrion Recent Developments

Table 113. Pfizer (Hospira) Corporation Information

Table 114. Pfizer (Hospira) Description and Major Businesses

Table 115. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 116. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

Table 117. Pfizer (Hospira) Recent Developments

Table 118. 3SBIO Corporation Information

Table 119. 3SBIO Description and Major Businesses

Table 120. 3SBIO Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 121. 3SBIO Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

Table 122. 3SBIO Recent Developments

Table 123. Novartis (Sandoz) Corporation Information

Table 124. Novartis (Sandoz) Description and Major Businesses

Table 125. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 126. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

Table 127. Novartis (Sandoz) Recent Developments

Table 128. Dr Reddy’s Corporation Information

Table 129. Dr Reddy’s Description and Major Businesses

Table 130. Dr Reddy’s Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 131. Dr Reddy’s Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

Table 132. Dr Reddy’s Recent Developments

Table 133. Celgen Biopharma Corporation Information

Table 134. Celgen Biopharma Description and Major Businesses

Table 135. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 136. Celgen Biopharma Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

Table 137. Celgen Biopharma Recent Developments

Table 138. Cadila Healthcare Corporation Information

Table 139. Cadila Healthcare Description and Major Businesses

Table 140. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 141. Cadila Healthcare Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

Table 142. Cadila Healthcare Recent Developments

Table 143. Hisun Pharma Corporation Information

Table 144. Hisun Pharma Description and Major Businesses

Table 145. Hisun Pharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 146. Hisun Pharma Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

Table 147. Hisun Pharma Recent Developments

Table 148. Torrent Pharmaceuticals Corporation Information

Table 149. Torrent Pharmaceuticals Description and Major Businesses

Table 150. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)

Table 151. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Model Numbers, Pictures, Descriptions and Specifications

Table 152. Torrent Pharmaceuticals Recent Developments

Table 153. Key Raw Materials Lists

Table 154. Raw Materials Key Suppliers Lists

Table 155. Biosimilar Monoclonal Antibodies Distributors List

Table 156. Biosimilar Monoclonal Antibodies Customers List

Table 157. Biosimilar Monoclonal Antibodies Market Trends

Table 158. Biosimilar Monoclonal Antibodies Market Drivers

Table 159. Biosimilar Monoclonal Antibodies Market Challenges

Table 160. Biosimilar Monoclonal Antibodies Market Restraints

Table 161. Research Programs/Design for This Report

Table 162. Key Data Information from Secondary Sources

Table 163. Key Data Information from Primary Sources

List of Figures

Figure 1. Biosimilar Monoclonal Antibodies Product Picture

Figure 3. Global Biosimilar Monoclonal Antibodies Market Share by Type in 2021 & 2028

Figure 3. Infliximab Product Picture

Figure 4. Rituximab Product Picture

Figure 5. Trastuzumab Product Picture

Figure 6. Adalimumab Product Picture

Figure 7. Other Product Picture

Figure 8. Global Biosimilar Monoclonal Antibodies Market Share by Application in 2021 & 2028

Figure 9. Oncology

Figure 10. Autoimmune Disease

Figure 11. Other

Figure 12. Biosimilar Monoclonal Antibodies Report Years Considered

Figure 13. Global Biosimilar Monoclonal Antibodies Sales 2017-2028 (K Units)

Figure 14. Global Biosimilar Monoclonal Antibodies Revenue, (US$ Million), 2017 VS 2021 VS 2028

Figure 15. Global Biosimilar Monoclonal Antibodies Revenue 2017-2028 (US$ Million)

Figure 16. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region in Percentage: 2021 Versus 2028

Figure 17. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2017-2022)

Figure 18. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2023-2028)

Figure 19. North America Biosimilar Monoclonal Antibodies Sales YoY (2017-2028) & (K Units)

Figure 20. North America Biosimilar Monoclonal Antibodies Revenue YoY (2017-2028) & (US$ Million)

Figure 21. Europe Biosimilar Monoclonal Antibodies Sales YoY (2017-2028) & (K Units)

Figure 22. Europe Biosimilar Monoclonal Antibodies Revenue YoY (2017-2028) & (US$ Million)

Figure 23. Asia-Pacific Biosimilar Monoclonal Antibodies Sales YoY (2017-2028) & (K Units)

Figure 24. Asia-Pacific Biosimilar Monoclonal Antibodies Revenue YoY (2017-2028) & (US$ Million)

Figure 25. Latin America Biosimilar Monoclonal Antibodies Sales YoY (2017-2028) & (K Units)

Figure 26. Latin America Biosimilar Monoclonal Antibodies Revenue YoY (2017-2028) & (US$ Million)

Figure 27. Middle East & Africa Biosimilar Monoclonal Antibodies Sales YoY (2017-2028) & (K Units)

Figure 28. Middle East & Africa Biosimilar Monoclonal Antibodies Revenue YoY (2017-2028) & (US$ Million)

Figure 29. The Biosimilar Monoclonal Antibodies Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021

Figure 30. The Top 5 and 10 Largest Manufacturers of Biosimilar Monoclonal Antibodies in the World: Market Share by Biosimilar Monoclonal Antibodies Revenue in 2021

Figure 31. Global Biosimilar Monoclonal Antibodies Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021

Figure 32. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2017-2028)

Figure 33. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2017-2028)

Figure 34. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2017-2028)

Figure 35. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2017-2028)

Figure 36. North America Biosimilar Monoclonal Antibodies Sales Market Share by Type (2017-2028)

Figure 37. North America Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2017-2028)

Figure 38. North America Biosimilar Monoclonal Antibodies Sales Market Share by Application (2017-2028)

Figure 39. North America Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2017-2028)

Figure 40. North America Biosimilar Monoclonal Antibodies Sales Share by Country (2017-2028)

Figure 41. North America Biosimilar Monoclonal Antibodies Revenue Share by Country (2017-2028)

Figure 42. U.S. Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 43. Canada Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 44. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Type (2017-2028)

Figure 45. Europe Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2017-2028)

Figure 46. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Application (2017-2028)

Figure 47. Europe Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2017-2028)

Figure 48. Europe Biosimilar Monoclonal Antibodies Sales Share by Country (2017-2028)

Figure 49. Europe Biosimilar Monoclonal Antibodies Revenue Share by Country (2017-2028)

Figure 50. Germany Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 51. France Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 52. U.K. Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 53. Italy Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 54. Russia Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 55. Asia Pacific Biosimilar Monoclonal Antibodies Sales Market Share by Type (2017-2028)

Figure 56. Asia Pacific Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2017-2028)

Figure 57. Asia Pacific Biosimilar Monoclonal Antibodies Sales Market Share by Application (2017-2028)

Figure 58. Asia Pacific Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2017-2028)

Figure 59. Asia Pacific Biosimilar Monoclonal Antibodies Sales Share by Region (2017-2028)

Figure 60. Asia Pacific Biosimilar Monoclonal Antibodies Revenue Share by Region (2017-2028)

Figure 61. China Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 62. Japan Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 63. South Korea Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 64. India Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 65. Australia Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 66. Taiwan Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 67. Indonesia Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 68. Thailand Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 69. Malaysia Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 70. Philippines Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 71. Latin America Biosimilar Monoclonal Antibodies Sales Market Share by Type (2017-2028)

Figure 72. Latin America Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2017-2028)

Figure 73. Latin America Biosimilar Monoclonal Antibodies Sales Market Share by Application (2017-2028)

Figure 74. Latin America Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2017-2028)

Figure 75. Latin America Biosimilar Monoclonal Antibodies Sales Share by Country (2017-2028)

Figure 76. Latin America Biosimilar Monoclonal Antibodies Revenue Share by Country (2017-2028)

Figure 77. Mexico Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 78. Brazil Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 79. Argentina Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 80. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Market Share by Type (2017-2028)

Figure 81. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2017-2028)

Figure 82. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Market Share by Application (2017-2028)

Figure 83. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2017-2028)

Figure 84. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Share by Country (2017-2028)

Figure 85. Middle East and Africa Biosimilar Monoclonal Antibodies Revenue Share by Country (2017-2028)

Figure 86. Turkey Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 87. Saudi Arabia Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 88. U.A.E Biosimilar Monoclonal Antibodies Revenue (2017-2028) & (US$ Million)

Figure 89. Biosimilar Monoclonal Antibodies Value Chain

Figure 90. Biosimilar Monoclonal Antibodies Production Process

Figure 91. Channels of Distribution

Figure 92. Distributors Profiles

Figure 93. Bottom-up and Top-down Approaches for This Report

Figure 94. Data Triangulation

Figure 95. Key Executives Interviewed